Annual report pursuant to Section 13 and 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)

Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Total revenues	$ 50,382	$ 59,221	$ 50,126	$ 36,516	$ 56,404	$ 59,694	$ 78,854	$ 46,592	$ 196,245	$ 241,544	$ 163,562
Royalties
Disaggregation of Revenue [Line Items]
Total revenues									72,527	48,927	33,796
Kyprolis
Disaggregation of Revenue [Line Items]
Total revenues									30,116	27,472	25,164
Evomela
Disaggregation of Revenue [Line Items]
Total revenues									10,197	10,079	6,377
Teriparatide injection
Disaggregation of Revenue [Line Items]
Total revenues									15,785	5,260	0
Rylaze
Disaggregation of Revenue [Line Items]
Total revenues									8,796	2,420	0
Other
Disaggregation of Revenue [Line Items]
Total revenues									7,633	3,696	2,255
Captisol
Disaggregation of Revenue [Line Items]
Total revenues									104,495	164,250	109,959
Captisol - Core
Disaggregation of Revenue [Line Items]
Total revenues									16,429	23,423	24,566
Captisol - COVID
Disaggregation of Revenue [Line Items]
Total revenues									88,066	140,827	85,393
Contract revenue
Disaggregation of Revenue [Line Items]
Total revenues									19,223	28,367	19,807
Service Revenue
Disaggregation of Revenue [Line Items]
Total revenues									1,117	3,737	9,330
License Fees
Disaggregation of Revenue [Line Items]
Total revenues									2,849	634	119
Milestone
Disaggregation of Revenue [Line Items]
Total revenues									9,150	17,584	5,217
Other
Disaggregation of Revenue [Line Items]
Total revenues									$ 6,107	$ 6,412	$ 5,141